CAMBRIDGE, Mass., Oct. 22, 2013 /PRNewswire/ -- Flagship VentureLabs ™ announces the launch of Pronutria after two years of development in stealth mode and $10.8 million in Series A investments during that period from Flagship Ventures. The company is currently advancing into human clinical testing its lead ProNutrein™ programs to improve health and treat significant medical conditions mediated by amino acid biology, including muscle, metabolic, and rare diseases. Pronutria has created a revolutionary platform for identifying proteins in the human diet that, when delivered in pure form, provide a preferred balance of amino acids that elicit a pharmacological effect, important in the setting of a wide range of diseases. ProNutrein™ products offer a vast untapped source of safe, breakthrough medicines. ProNutrein™ products are naturally occurring, orally consumed pure protein products that trigger pharmacological effects through precise and reproducible delivery of specific amino acids. The ProNutrein™ product platform leverages a wealth of advanced biotechnology tools, typically applied to drug discovery, that Pronutria has applied to the human diet for the first time, allowing for the identification and development of a large family of pharmaconutrients - nutrients identified in food that can be developed initially as medical foods or dietary supplements and eventually as drugs. The company's discovery strategy builds upon decades of amino acid clinical trial data that validate the potent health benefits of pure and precise amino acid delivery for many indications. By tapping into the enormous power of amino acid pharmacology, and with the large library of protein nutrients that can deliver it, Pronutria plans to build pharmaconutrients into a major class of new products. Amino acid mediated biology is at the heart of a wide range of medical conditions, and both drugs and medical foods that affect this biology can play a critical role in their treatment and support. Patients with rare diseases, such phenylketonuria, have an inability to properly metabolize specific amino acids. Other diseases, such as inflammatory bowel disease and cystic fibrosis, suffer from impaired amino acid uptake which exacerbates disease. And millions suffer from muscle and metabolic diseases where there is a mechanistic link between amino acid biology and the underlying disease pathophysiology. The ProNutrein™ product platform allows for the tailored selection of proteins ideal for each of these indications that could play a significant role in disease prevention and treatment.